Meeting
2023 ASCO Annual Meeting
Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.
Authors
Mothaffar F. Rimawi
Lester and Sue Smith Breast Center, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
Mothaffar F. Rimawi , Erika P. Hamilton , Sara A. Hurvitz , Douglas Kanter Marks , Anthony D. Elias , Timothy J. Pluard , Nashat Y. Gabrail , John Patterson , Stephanie Greene , Qingping Zeng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT03950570
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1092)
DOI
10.1200/JCO.2023.41.16_suppl.1092
Abstract #
1092
Poster Bd #
313
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.
First Author: Nashat Y. Gabrail
Poster
2023 ASCO Annual Meeting
Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.
First Author: Sarina A. Piha-Paul
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2023 ASCO Annual Meeting
First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors.
First Author: Jifang Gong